ANAFIT 1 MG

The primary purpose of Anafit 1 mg (which contains the active ingredient Anastrozole) is as a targeted hormonal therapy classified as a non-steroidal aromatase inhibitor.

It lowers estrogen levels in the body to treat hormone-dependent conditions.

1. Primary Medical Indication

1. Hormone Receptor-Positive (HR+) Breast Cancer: Anafit 1 mg is primarily prescribed to treat postmenopausal women with early-stage or advanced hormone-sensitive breast cancer.
2. Mechanism of Action: Many postmenopausal breast cancer cells rely on estrogen to grow and replicate. Anastrozole blocks the enzyme aromatase, preventing the conversion of adrenal hormones into estrogen. This "starves" estrogen-dependent cancer cells, inhibiting tumor growth and lowering the risk of recurrence.

2. Specialist Indications

1. Management of Hyperestrogenism in Men: In specialized clinical contexts—such as men undergoing testosterone replacement therapy (TRT) or specific hormonal treatments—Anafit 1 mg is sometimes used off-label to control excess estrogen resulting from the aromatization of testosterone into estradiol.
2. Male Gynecomastia: Prescribed in certain cases to suppress elevated estradiol levels that cause painful glandular breast enlargement in men.

Aromatase inhibitor that reduces estrogen production and is primarily used in hormone-sensitive breast cancer treatment.